Drugs / JWATM204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06144385 | Mar 2022 → Mar 2024 | hepatocellular carcinoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JWATM204 | “JWATM204 is a novel GPC3-targeted CAR T cell therapy developed on the Antibody Redirected T Cells with Endogenous Modular Immune Signaling (ARTEMIS) T-cell platform, combining...” PMID 41859477 ↗ Dec 2025 |
| Modality | Cell therapy | “JWATM204 is a novel GPC3-targeted CAR T cell therapy developed on the Antibody Redirected T Cells with Endogenous Modular Immune Signaling (ARTEMIS) T-cell platform” PMID 41859477 ↗ Dec 2025 |
| Route | Intravenous | “After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.” NCT06144385 ↗ |